Bennett A Caughey
Overview
Explore the profile of Bennett A Caughey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
927
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caughey B, Parikh A
J Natl Compr Canc Netw
. 2024 Dec;
22(10).
PMID: 39681074
In patients with surgically resectable colon cancer (CC), clinicopathologic characteristics translate into cancer staging and predict recurrence risk. Adjuvant chemotherapy reduces the risk of recurrence and is offered to high-risk...
2.
Kumar A, Owen J, Sloat N, Maynard E, Hill V, Hubbard C, et al.
Curr Oncol
. 2024 Nov;
31(11):7244-7257.
PMID: 39590164
Targeting tumor-specific molecular alterations has shown significant clinical benefit. Molecular tumor boards (MTBs) connect cancer patients with personalized treatments and clinical trials. However, rural cancer centers often have limited access...
3.
Lin C, Zhou K, Green M, Caughey B, Strickler J, Datto M, et al.
Hematol Rep
. 2024 Oct;
16(4):603-611.
PMID: 39449302
Background: Comprehensive genomic profiling (CGP) is frequently adopted to direct the clinical care of myeloid neoplasms and solid tumors, but its utility in the care of lymphoid and histiocytic cancers...
4.
Caughey B, Strickler J
Drugs
. 2023 Dec;
84(1):27-44.
PMID: 38109010
Kirsten rat sarcoma virus (KRAS) is one of the most important and frequently mutated oncogenes in cancer and the mutational prevalence is especially high in many gastrointestinal malignancies, including colorectal...
5.
Caughey B, Umemoto K, Green M, Ikeda M, Lowe M, Ueno M, et al.
J Gastrointest Oncol
. 2023 Nov;
14(5):2083-2096.
PMID: 37969845
Background: Evaluation for activating mutations in , , and in colorectal cancer (CRC) and in in pancreatic ductal adenocarcinoma (PDAC) is essential for clinical care. Plasma cell-free DNA (cfDNA) next-generation...
6.
Xu R, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al.
Nat Mater
. 2017 Oct;
16(11):1155-1161.
PMID: 29035356
An effective blood-based method for the diagnosis and prognosis of hepatocellular carcinoma (HCC) has not yet been developed. Circulating tumour DNA (ctDNA) carrying cancer-specific genetic and epigenetic aberrations may enable...
7.
Hao X, Luo H, Krawczyk M, Wei W, Wang W, Wang J, et al.
Proc Natl Acad Sci U S A
. 2017 Jun;
114(28):7414-7419.
PMID: 28652331
The ability to identify a specific cancer using minimally invasive biopsy holds great promise for improving the diagnosis, treatment selection, and prediction of prognosis in cancer. Using whole-genome methylation data...
8.
Yin A, Peng C, Zhao X, Caughey B, Yang J, Liu J, et al.
Proc Natl Acad Sci U S A
. 2015 Nov;
112(47):14670-5.
PMID: 26554006
Noninvasive prenatal testing (NIPT) using sequencing of fetal cell-free DNA from maternal plasma has enabled accurate prenatal diagnosis of aneuploidy and become increasingly accepted in clinical practice. We investigated whether...
9.
Bejar R, Stevenson K, Caughey B, Abdel-Wahab O, Steensma D, Galili N, et al.
J Clin Oncol
. 2012 Aug;
30(27):3376-82.
PMID: 22869879
Purpose: A subset of patients with myelodysplastic syndromes (MDS) who are predicted to have lower-risk disease as defined by the International Prognostic Scoring System (IPSS) demonstrate more aggressive disease and...